SinoMab BioScience Limited (“Sinomab” or “the Company”, 3681.HK) is successfully listed on Hong Kong Stock Exchange on 12th Nov, 2019. The pre-green shoe offering size was US$ 176 million and the post-green shoe offering size is US$203 million (the Offering). SinoMab BioScience Limited is the first Hong Kong based biotech company listed under Chapter 18A and the first biotech company focusing on immunological diseases on HKEX, being a remarkable milestone. CICC acted as Lead sponsor, Lead global coordinator, Joint bookrunner, and Joint lead manager.

Sinomab is a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. Sinomab has built a pipeline of complementary mAb-based biologics and new chemical entities with the potential of “first-in-class” and “first-in-target”. 

The Company has developed a product pipeline comprising 6 drug candidates as of the Latest Practicable Date, of which 2 entered clinical stage, targeting various immunological diseases such as RA, SLE and allergic asthma with largely unmet medical needs and total addressable markets. Our flagship product SM03 is currently in Phase III clinical trial for RA in China and it is the first and only clinical stage anti-CD22 mAb for the treatment of RA in the world. Through its Hong Kong-based R&D and PRC-based manufacturing capabilities, the Company’s vision is to become a global leader in the innovation of therapeutics for immunological diseases.

As the Joint Sponsor and Lead Global Coordinator of the Offering, with abundant experience of completed projects and effective communication with HKEx, CICC was responsible for documents submission and communication with regulatory authorities. As the Lead Sponsor, CICC continued to escort and advise the Company during the reviewing process of HKEx, while keeping closely communication with HKEx and organizing all parties and took the lead in each work line to ensure the overall progress of the execution: it only took 8 months from the project kick-off to listing as CICC effectively promoted the project progress. 

CICC was responsible for investor recommendation and assisted in introducing important cornerstone investor Yunnan Baiyao. It is the first cornerstone investment of Yunnan Baiyao in innovative drug field. By leveraging its abundant domestic and international resources and exploring investors’ needs, CICC introduced multiple high-profile institutions and met all demands in the beginning of the bookbuilding process. CICC introduced multiple International long-term funds, large insurance institutions, well-known hedge funds and professional medical investors, which was highly recognized by the Company and investors.

With its rich experience in project execution and strong edge on comprehensive service, successfully assisting Sinomab Bioscience in listing on HKEx, CICC has won high praise and extensive recognition from the client in this deal. 

As a leading investment bank with “Chinese Roots, International Reach”, CICC will continue to utilize its capital market expertise as well as its seamless cooperation of onshore and offshore businesses to provide continuous support to our customers in terms of introduction of global investors, reaching international capital market, and promoting global business development.